Loading organizations...
M42 delivers integrated healthcare and medical services, leveraging artificial intelligence, technology, and genomics to provide precise preventive and predictive care. The company combines advanced medical and data-centric technologies with patient services across a global network. Its core approach centers on innovation in health to enhance well-being worldwide.
Formed in 2023, M42 emerged from the strategic combination of G42 Healthcare and Mubadala Health. This union was driven by an insight to consolidate significant healthcare assets and technological capabilities, establishing a unified entity poised to lead in health tech. The merger brought together extensive operational experience and advanced research.
M42 serves a broad base of patients globally through its extensive network of facilities across numerous countries. The company's long-term vision is to drive a new era of health advancement, utilizing its integrated platform to transform healthcare delivery and make cutting-edge medical solutions accessible on a global scale.
M42 has 1 tracked investment across 1 company. The latest tracked deal is $76.0M Series B in Juvenescence in May 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 26, 2025 | Juvenescence | $76.0M Series B | M42 | — |